vs
CHEESECAKE FACTORY INC（CAKE）与GLOBUS MEDICAL INC（GMED）财务数据对比。点击上方公司名可切换其他公司
CHEESECAKE FACTORY INC的季度营收约是GLOBUS MEDICAL INC的1.2倍（$961.6M vs $826.4M），GLOBUS MEDICAL INC净利率更高（17.0% vs 3.0%，领先14.0%），GLOBUS MEDICAL INC同比增速更快（25.7% vs -73.2%），过去两年GLOBUS MEDICAL INC的营收复合增速更高（16.7% vs 7.6%）
芝士蛋糕工厂（The Cheesecake Factory）是美国知名的餐饮连锁及芝士蛋糕分销企业，目前在全球运营370家全服务餐厅，其中218家为芝士蛋糕工厂品牌门店，47家为North Italia品牌门店，其余105家为其他品牌门店。此外公司在加利福尼亚州卡拉巴萨斯及北卡罗来纳州落基山城设有两座烘焙生产基地。
Globus Medical是总部位于美国宾夕法尼亚州奥杜邦的上市骨科医疗器械企业，专注于相关产品的设计、研发与商业化，助力外科医生为肌肉骨骼系统疾病患者提供治疗方案，促进患者康复。
CAKE vs GMED — 直观对比
营收规模更大
CAKE
是对方的1.2倍
$826.4M
营收增速更快
GMED
高出98.9%
-73.2%
净利率更高
GMED
高出14.0%
3.0%
两年增速更快
GMED
近两年复合增速
7.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $961.6M | $826.4M |
| 净利润 | $28.8M | $140.6M |
| 毛利率 | — | 68.4% |
| 营业利润率 | 3.5% | 20.5% |
| 净利率 | 3.0% | 17.0% |
| 营收同比 | -73.2% | 25.7% |
| 净利润同比 | -30.1% | 430.4% |
| 每股收益（稀释后） | $0.60 | $1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CAKEGMED
| Q1 26 | $961.6M | — | ||
| Q4 25 | — | $826.4M | ||
| Q3 25 | $907.2M | $769.0M | ||
| Q2 25 | $927.2M | $745.3M | ||
| Q1 25 | — | $598.1M | ||
| Q4 24 | $865.5M | $657.3M | ||
| Q3 24 | $904.0M | $625.7M | ||
| Q2 24 | $891.2M | $629.7M |
净利润CAKEGMED
| Q1 26 | $28.8M | — | ||
| Q4 25 | — | $140.6M | ||
| Q3 25 | $31.9M | $119.0M | ||
| Q2 25 | $32.9M | $202.8M | ||
| Q1 25 | — | $75.5M | ||
| Q4 24 | $30.0M | $26.5M | ||
| Q3 24 | $52.4M | $51.8M | ||
| Q2 24 | $33.2M | $31.8M |
毛利率CAKEGMED
| Q1 26 | — | — | ||
| Q4 25 | — | 68.4% | ||
| Q3 25 | — | 67.2% | ||
| Q2 25 | — | 66.6% | ||
| Q1 25 | — | 67.3% | ||
| Q4 24 | — | 59.9% | ||
| Q3 24 | — | 56.8% | ||
| Q2 24 | — | 58.7% |
营业利润率CAKEGMED
| Q1 26 | 3.5% | — | ||
| Q4 25 | — | 20.5% | ||
| Q3 25 | 4.1% | 17.9% | ||
| Q2 25 | 5.6% | 10.2% | ||
| Q1 25 | — | 16.2% | ||
| Q4 24 | 3.9% | 9.2% | ||
| Q3 24 | 6.5% | 7.7% | ||
| Q2 24 | 4.4% | 7.9% |
净利率CAKEGMED
| Q1 26 | 3.0% | — | ||
| Q4 25 | — | 17.0% | ||
| Q3 25 | 3.5% | 15.5% | ||
| Q2 25 | 3.6% | 27.2% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | 3.5% | 4.0% | ||
| Q3 24 | 5.8% | 8.3% | ||
| Q2 24 | 3.7% | 5.0% |
每股收益（稀释后）CAKEGMED
| Q1 26 | $0.60 | — | ||
| Q4 25 | — | $1.01 | ||
| Q3 25 | $0.66 | $0.88 | ||
| Q2 25 | $0.67 | $1.49 | ||
| Q1 25 | — | $0.54 | ||
| Q4 24 | $0.61 | $0.19 | ||
| Q3 24 | $1.08 | $0.38 | ||
| Q2 24 | $0.68 | $0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $215.7M | $557.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $4.6B |
| 总资产 | — | $5.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CAKEGMED
| Q1 26 | $215.7M | — | ||
| Q4 25 | — | $557.2M | ||
| Q3 25 | $190.0M | $18.8M | ||
| Q2 25 | $135.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $52.2M | $890.1M | ||
| Q3 24 | $40.7M | $71.9M | ||
| Q2 24 | $60.2M | $82.5M |
股东权益CAKEGMED
| Q1 26 | — | — | ||
| Q4 25 | — | $4.6B | ||
| Q3 25 | $425.3M | $4.4B | ||
| Q2 25 | $339.4M | $4.3B | ||
| Q1 25 | — | $4.1B | ||
| Q4 24 | $396.4M | $4.2B | ||
| Q3 24 | $374.0M | $4.1B | ||
| Q2 24 | $332.4M | $4.0B |
总资产CAKEGMED
| Q1 26 | — | — | ||
| Q4 25 | — | $5.3B | ||
| Q3 25 | $3.2B | $5.1B | ||
| Q2 25 | $3.1B | $5.0B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | $2.9B | $5.3B | ||
| Q3 24 | $2.9B | $5.1B | ||
| Q2 24 | $2.8B | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $248.6M |
| 自由现金流经营现金流 - 资本支出 | — | $202.4M |
| 自由现金流率自由现金流/营收 | — | 24.5% |
| 资本支出强度资本支出/营收 | — | 5.6% |
| 现金转化率经营现金流/净利润 | — | 1.77× |
| 过去12个月自由现金流最近4个季度 | — | $588.8M |
8季度趋势，按日历期对齐
经营现金流CAKEGMED
| Q1 26 | — | — | ||
| Q4 25 | — | $248.6M | ||
| Q3 25 | $147.5M | $249.7M | ||
| Q2 25 | $78.9M | $77.9M | ||
| Q1 25 | — | $177.3M | ||
| Q4 24 | $79.9M | $210.3M | ||
| Q3 24 | $27.7M | $203.7M | ||
| Q2 24 | $66.7M | $54.3M |
自由现金流CAKEGMED
| Q1 26 | — | — | ||
| Q4 25 | — | $202.4M | ||
| Q3 25 | $69.2M | $213.9M | ||
| Q2 25 | $36.1M | $31.3M | ||
| Q1 25 | — | $141.2M | ||
| Q4 24 | $25.7M | $193.2M | ||
| Q3 24 | $-1.5M | $161.7M | ||
| Q2 24 | $29.6M | $26.5M |
自由现金流率CAKEGMED
| Q1 26 | — | — | ||
| Q4 25 | — | 24.5% | ||
| Q3 25 | 7.6% | 27.8% | ||
| Q2 25 | 3.9% | 4.2% | ||
| Q1 25 | — | 23.6% | ||
| Q4 24 | 3.0% | 29.4% | ||
| Q3 24 | -0.2% | 25.8% | ||
| Q2 24 | 3.3% | 4.2% |
资本支出强度CAKEGMED
| Q1 26 | — | — | ||
| Q4 25 | — | 5.6% | ||
| Q3 25 | 8.6% | 4.7% | ||
| Q2 25 | 4.6% | 6.2% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | 6.3% | 2.6% | ||
| Q3 24 | 3.2% | 6.7% | ||
| Q2 24 | 4.2% | 4.4% |
现金转化率CAKEGMED
| Q1 26 | — | — | ||
| Q4 25 | — | 1.77× | ||
| Q3 25 | 4.62× | 2.10× | ||
| Q2 25 | 2.40× | 0.38× | ||
| Q1 25 | — | 2.35× | ||
| Q4 24 | 2.66× | 7.94× | ||
| Q3 24 | 0.53× | 3.93× | ||
| Q2 24 | 2.01× | 1.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAKE
暂无分部数据
GMED
| Other | $391.8M | 47% |
| Nevro Merger Agreement | $293.6M | 36% |
| Enabling Technologies | $141.0M | 17% |
